GARDP and the University of Liverpool plan to boost collaboration on AMR

The Global Antibiotic Research and Development Partnership (GARDP) and the University of Liverpool have signed a Memorandum of Understanding (MOU) to collaborate on new projects to address antimicrobial resistance (AMR) for the benefit of public health.

Since 2018, GARDP and the University of Liverpool have been working together to advance new treatment options for newborns with sepsis. Their research—published in leading peer-reviewed journals such as Archives of Disease in Childhood and the Journal of Antimicrobial Chemotherapy—has laid the groundwork for GARDP’s upcoming global clinical trial on neonatal sepsis. The trial will rank the safety and effectiveness of new combinations of three existing antibiotics against commonly used regimens to treat babies with sepsis. New treatment options are needed to respond to growing drug resistance to the current WHO-recommended regimen, especially in many low- and middle-income countries.